Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGIV sub-protocol for hospitalized patients with mpox or smallpox
jRCTs031240111Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Human vaccinia virus immune globulin in mpox and smallpox, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Skin lesion PCR clearance at day 14. Started Jan 2026; status: recruiting.
02
Drugs
Human vaccinia virus immune globulin
03
Conditions
mpoxsmallpox
Beyond the preview
Go deeper on jRCTs031240111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240111.